September 27, 2024
Knte stock – Kinnate Biopharma Inc. Stock Company Profile
Knte stock – Kinnate Biopharma Inc., as a biopharmaceutical firm, specializes in discovering and advancing small molecule kinase inhibitors for treating cancers defined by genomics in the U.S. The Company is generating KIN-2787, a fast-track fibrosarcoma inhibitor for patients with
- 8
- 0
- 0